TISSUE REGENIX GROUP PLC — Board/Management Information 2013

Mar 11, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6386Z

Tissue Regenix Group PLC

11 March 2013

Director change

York, 11 March, 2013

Tissue Regenix announced today that Alex Stevenson has stepped down as a non-executive director of Tissue Regenix Group plc ('TRX') with immediate effect.

A process is well underway to appoint new independent non-executive directors to replace Alex Stevenson and Mike Bretherton, who resigned in February 2013.

John Samuel, Executive Chairman of Tissue Regenix Group plc commented: "I would like to thank Alex for his help and support at Tissue Regenix where he has been a non-executive director since December 2007.  His experience as both a scientist and an investor were invaluable during the early stage development of the company."

-ENDS-

For Further Information

Tissue Regenix Group plc:                                                         0190 443 5176

Antony Odell

Peel Hunt LLP (Nominated Adviser):                                       0207 418 8900

James Steel

Vijay Barathan

Newgate Communications:

Alistair Kellie                                                                                0755 765 1840

Andrew Adie                                                                                0797 025 6512

Martin Greig                                                                                0758 422 1513

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®) technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOADVLFBXXFBBBQ